Fig. 1 · Structure

Documents & Downloads

Crenolanib (CP-868596)

Cat. No. A11052 CAS 670220-88-9

PDGFR/FLT3 Inhibitor

Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.

In Stock

Publications for Crenolanib

1 publication citing this product

  1. N Naganna, .et al. , EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Crenolanib binds FLT3, including FLT3-ITD and selected kinase-domain mutants. A purified-kinase study reported Kd values of 0.15 nM for WT FLT3 and 0.26 nM for FLT3-ITD, with weaker binding to FLT3-ITD/F691L (22 nM). Preferential binding to active over inactive Abl provided indirect evidence consistent with type I inhibition. These binding endpoints are distinct from cellular IC50 values. [1]

Crenolanib also suppresses PDGF-evoked signaling in human dermal fibroblasts. At 100 nM, pretreatment attenuated ERK1/2 and Akt phosphorylation induced by PDGFAA or PDGFBB. This downstream cellular experiment supports PDGF-pathway activity; it does not establish a PDGFR binding constant or exclude off-target contributions. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PDGFRα (CHO cells) Kd 2.1 nM
PDGFRβ (CHO cells) Kd 3.2 nM
FLT3 Kd 0.74 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 1.3 nM Antiproliferative activity against mouse BaF3 FLT3-ITD cells assessed as reduction in cell viability measured after 72 hrs by MTS assay [PMID: 32659083]
Jurkat IC50 > 1 μM Cytotoxicity in human Jurkat cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay [PMID: 30742435]
MOLM-13 IC50 2 nM Antiproliferative activity against human MOLM-13 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay [PMID: 32659083]
MOLM-13 IC50 2.9 nM Cytotoxicity against human MOLM-13 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay [PMID: 32659083]
MOLM-13 IC50 4.9 nM Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs [PMID: 32659083]
MOLM-14 IC50 2 nM Antiproliferative activity against human MOLM-14 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay [PMID: 32659083]
MOLM-14 IC50 2 nM Cytotoxicity against human MOLM-14 cells assessed as reduction in cell viability incubated for 72 hrs [PMID: 32659083]
MV4-11 IC50 0.92 nM Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay [PMID: 32659083]
MV4-11 IC50 1.3 nM Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay [PMID: 32659083]
MV4-11 IC50 12 nM Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay [PMID: 30742435]
THP-1 IC50 > 1 μM Cytotoxicity in human THP1 cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay [PMID: 30742435]

11 records · Scroll to view more

Crenolanib (CP-868596) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Crenolanib (CP-868596) from 4 published references. In vitro models include MV4-11, MOLM-14, MOLM-14, and MOLM-14.

Crenolanib (CP-868596) In Vitro Studies

In an AML comparator study reporting Adooq-sourced crenolanib, cellular IC50 values were 3.1 ± 0.06 nM in MV4-11 and 4.5 ± 0.8 nM in MOLM-14, versus 6.6 ± 0.03 nM and 15.6 ± 0.4 nM in MOLM-14 carrying additional D835Y and F691L mutations, respectively (mean ± SD). Methods specify a 72 h exposure followed by CellTitre-Blue, although Results call the assay MTT; the values are retained as the reported viability/antiproliferative endpoints. Supplier attribution does not establish a catalog number, salt or current lot. [3]

A separate study found approximately 10 nM cellular IC50 activity in FLT3-ITD AML lines Molm14 and MV4;11 after 48 h. KIT-driven HMC 1.1 and HMC 1.2 cells were much less responsive at 100 nM. This comparison supports model-dependent cellular selectivity; loss of viability at higher concentrations prevents an absolute KIT-sparing interpretation. [4]

Crenolanib comparator activity in AML cell lines

Cell-based study · MV4-11, MOLM-14, MOLM-14 (FLT3-ITD, D835Y), and MOLM-14 (FLT3-ITD, F691L) [3]

The reported crenolanib IC50 values were higher in the two secondary-mutant MOLM-14 models than in parental MOLM-14. These are antiproliferative/viability assay endpoints, not administered concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MV4-11 antiproliferative activityIC50 (mean ± SD) 3.1 ± 0.06 nM[3]
MOLM-14 antiproliferative activityIC50 (mean ± SD) 4.5 ± 0.8 nM[3]
MOLM-14 (ITD, D835Y) antiproliferative activityIC50 (mean ± SD) 6.6 ± 0.03 nM[3]
MOLM-14 (ITD, F691L) antiproliferative activityIC50 (mean ± SD) 15.6 ± 0.4 nM[3]

Literature-Reported Treatment Conditions

Treatment concentration
Serially diluted compound; highest tested concentration 10 μM (assay method).
Exposure duration
72 h exposure, followed by 4 h after addition of viability reagent.
Method
CellTitre-Blue fluorescence per section 2.2; do not relabel as a direct cell count or apoptosis assay.
Vehicle
DMSO stock and DMSO-normalized control; final DMSO percentage not reported in section 2.2.
Co-treatment
Crenolanib alone; other inhibitors were separate comparators.
Reported limits
Exact salt, catalog number and lot absent from the selected material description. Figure 4 reports triplicates; independence of those replicates is not specified. Results call the assay MTT, whereas section 2.2 specifies CellTitre-Blue.
Methods and source locations

Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib

Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.

Table 1, crenolanib row and header; sections 2.1, 2.2 and 3; Figures 2 and 4

MV4-11 antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption

MOLM-14 antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption

MOLM-14 (ITD, D835Y) antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption

MOLM-14 (ITD, F691L) antiproliferative activity: Table 1 reports mean ± SD; assay triplicates. Section 2.2 specifies CellTitre-Blue fluorescence normalized to DMSO with nonlinear regression; Results describe MTT, an unresolved labeling inconsistency. — Table 1, crenolanib row; section 2.2; Figure 4 caption

FLT3 binding and evidence consistent with type I inhibition

Biochemical assay · Purified FLT3 variants; phosphorylated and nonphosphorylated WT Abl and Abl Q252H [1]

Crenolanib bound FLT3 variants with different affinities. Preferential binding to active Abl was used as indirect evidence for type I properties; it is not a direct FLT3 co-crystal measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
WT FLT3 binding affinityKd 0.15 nM[1]
FLT3-ITD binding affinityKd 0.26 nM[1]
FLT3-ITD/D835V binding affinityKd 3.6 nM[1]
FLT3-ITD/F691L binding affinityKd 22 nM[1]
Active versus inactive WT Abl bindingKd; active/inactive ratio 140 nM versus 430 nM; ratio 0.33[1]
Active versus inactive Abl Q252H bindingKd; active/inactive ratio 36 nM versus 100 nM; ratio 0.36[1]

Literature-Reported Treatment Conditions

Method
In vitro kinase binding; Kd values are endpoints, not treatment doses.
Vehicle
DMSO formulation reported for in vitro assays.
Co-treatment
Single-agent binding experiments.
Reported limits
Binding titration concentrations, exposure time and replicate details not retrieved from the supplement; not supplied by inference.
Methods and source locations

Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib

Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.

Table 1; Methods: Binding affinity for FLT3 and Abl variants; Results: Crenolanib is a FLT3 inhibitor with type I properties

WT FLT3 binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes

FLT3-ITD binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes

FLT3-ITD/D835V binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes

FLT3-ITD/F691L binding affinity: Commercial KdELECT binding assay; apparent dissociation constant. — Table 1, FLT3 variant rows and footnotes

Active versus inactive WT Abl binding: KdELECT; phosphorylated active versus nonphosphorylated inactive Abl. — Table 1, Abl variant rows; Results: type I properties

Active versus inactive Abl Q252H binding: KdELECT; active versus inactive Abl Q252H. — Table 1, Abl variant rows; Results: type I properties

Differential viability response in FLT3-ITD and KIT-driven cells

Cell-based study · Molm14 and MV4;11 FLT3-ITD AML lines; HMC 1.1 (KIT V560G) and HMC 1.2 (KIT V560G/D816V); K562 comparator [4]

Low-nanomolar viability inhibition in the FLT3-ITD lines contrasted with little effect at 100 nM in the KIT-driven lines. This is model-dependent cellular selectivity, not proof of exclusive kinase specificity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Molm14 and MV4;11 viabilityIC50 approximately 10 nM[4]
HMC 1.1 and HMC 1.2 proliferation/viabilityQualitative comparison No impact on proliferation reported at 100 nM[4]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series as plotted in Figure 2A; 100 nM KIT-line comparison.
Exposure duration
48 h
Method
Cell viability in RPMI 1640 plus 10% FCS per Cell-Viability Assay methods; same-experiment triplicates.
Co-treatment
Crenolanib alone.
Reported limits
Exact salt and lot not specified. Figure 2A vehicle composition is not identified. No exact fitted IC50 is inferred from curves.
Methods and source locations

Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib

Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.

Figure 2A and caption; Results: Crenolanib Is approximately 100-Fold More Selective for FLT3 than KIT; Methods: Inhibitors and Cell-Viability Assay

Molm14 and MV4;11 viability: 48 h normalized cell viability; approximate value explicitly stated in Results, not fitted from the image. — Figure 2A; corresponding Results paragraph

HMC 1.1 and HMC 1.2 proliferation/viability: 48 h normalized viability; Figure 2A includes K562. Error bars: SD of triplicates from the same experiment. — Figure 2A and caption; corresponding Results paragraph

Suppression of PDGF-evoked ERK and Akt signaling

Cell-based study · Cultured healthy-control human dermal fibroblasts stimulated with PDGFAA or PDGFBB [2]

Crenolanib attenuated PDGFAA- and PDGFBB-induced ERK1/2 and Akt phosphorylation. Ligand-only, crenolanib-only and unstimulated conditions, total ERK/Akt and β-actin are shown. These downstream endpoints support PDGF-pathway inhibition without assigning a receptor-binding potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PDGF-induced ERK1/2 and Akt phosphorylationImmunoblot/densitometry Both ligand-induced phosphorylation responses were inhibited[2]

Literature-Reported Treatment Conditions

Treatment concentration
Crenolanib 100 nM; PDGFAA or PDGFBB 10 ng/mL.
Exposure duration
1 h crenolanib pretreatment, followed by 30 min PDGF stimulation.
Method
Immunoblotting in healthy-control fibroblasts.
Co-treatment
Crenolanib with either PDGFAA or PDGFBB as agonist; ligand-only and basal controls.
Reported limits
Salt/form, lot and figure-specific vehicle are not established. Caption n = 3 per group is retained without assuming three independent donors.
Methods and source locations

Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib

Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.

Figure 2c and caption; Results: Crenolanib inhibits proliferation and migration of fibroblasts; Methods: Cell culture, Reagents, Immunoblotting

PDGF-induced ERK1/2 and Akt phosphorylation: Figure 2c: phospho- and total ERK1/2 and Akt, β-actin; relative values normalized to control, mean ± SD, n = 3 per group. No exact effect size transcribed. — Figure 2c and caption; corresponding Results paragraph

Crenolanib (CP-868596) In Vivo Studies

In female NSG mice bearing MV4-11-luc leukemia, crenolanib at 15 mg/kg intraperitoneally once daily, Monday to Friday for 3 weeks from day 17, delayed leukemia outgrowth and increased median survival from 34 to 51 days. Adding oral sorafenib (15 mg/kg on the same schedule) increased median survival to 62 days, compared with 53 days for sorafenib alone. The combination benefit cannot be attributed to crenolanib monotherapy. [1]

Crenolanib alone and with sorafenib in an AML xenograft

Animal study · Female NSG mice bearing MV4-11-luc leukemia; Figure 3 survival panel shows 5 initially at risk per group [1]

Crenolanib monotherapy delayed leukemia outgrowth and prolonged survival versus vehicle. The combination produced greater leukemia suppression and longer survival than either drug alone; those added effects belong to the combination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Overall survivalMedian survival Vehicle 34 days; sorafenib 53 days; crenolanib 51 days; combination 62 days[1]
MV4-11-luc leukemia burdenBioluminescence comparison Both single agents delayed outgrowth versus vehicle (P < .001); combination reduced burden versus vehicle or either single agent (P < .001)[1]

Conditions shared by the study groups

Treatment course
3 consecutive weeks beginning day 17
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlReference control for active regimensMedian survival 34 days.[1]
Crenolanib
15 mg/kg
Vehicle-treated groupMedian survival 51 days; delayed leukemia outgrowth versus vehicle.[1]
Sorafenib
15 mg/kg
Vehicle-treated groupMedian survival 53 days; delayed leukemia outgrowth versus vehicle.[1]
Crenolanib plus sorafenib
Crenolanib 15 mg/kg plus sorafenib 15 mg/kg
Vehicle-treated groupMedian survival 62 days; lower leukemia burden and longer survival than either single agent.[1]
Vehicle control
Model: Female NSG mice engrafted with MV4-11-luc cells
Reported limits: Vehicle composition not retrieved from SI. Figure 3C initial number at risk: 5 per group.
Crenolanib
Model: Female NSG mice engrafted with MV4-11-luc cells
Route: Intraperitoneal
Frequency: Once daily, Monday to Friday
Reported limits: Vehicle composition not retrieved from SI. Figure 3C initial number at risk: 5 per group.
Sorafenib
Model: Female NSG mice engrafted with MV4-11-luc cells
Route: Oral
Frequency: Once daily, Monday to Friday
Reported limits: Vehicle composition not retrieved from SI. Figure 3C initial number at risk: 5 per group.
Crenolanib plus sorafenib
Model: Female NSG mice engrafted with MV4-11-luc cells
Route: Crenolanib intraperitoneal; sorafenib oral
Frequency: Once daily, Monday to Friday
Reported limits: Vehicle composition not retrieved from SI. Figure 3C initial number at risk: 5 per group.
Methods and source locations

Compound reported in the paper: Crenolanib (CP-868596); Compound label in the paper: crenolanib

Results apply to the paper's tested crenolanib material and model. Exact equivalence to the catalog free-base material was not established.

Figure 3A-C and caption; Results: Combination of type I and II FLT3 inhibitors potentiates antileukemic activity in vivo; Methods: in vivo and statistical sections

Overall survival: Kaplan-Meier; Figure 3C. P = .0017 for each active regimen versus vehicle; combination versus crenolanib P = .0021, versus sorafenib P = .0026. — Figure 3C and caption; corresponding Results paragraph

MV4-11-luc leukemia burden: Noninvasive luciferase imaging; no exact photon values estimated from curves. — Figure 3A-B; corresponding Results paragraph

Vehicle control · Figure 3A-C and caption; corresponding Results paragraph

Crenolanib · Figure 3A-C and caption; corresponding Results paragraph

Sorafenib · Figure 3A-C and caption; corresponding Results paragraph

Crenolanib plus sorafenib · Figure 3A-C and caption; corresponding Results paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 670220-88-9
Applications PDGFR/FLT3 Inhibitor
Formula C26H29N5O2
Molecular Weight 443.5
Synonyms CP868596
SMILES
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 84 mg/mL (189.38 mM)
Water Insoluble
Ethanol 7 mg/mL (15.78 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Crenolanib (CP-868596) Research References

  1. [1] Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia Blood (2013). PMID: 24046014 DOI: 10.1182/blood-2013-07-513044 Source material
  2. [2] Makino K, Makino T, Stawski L, et al. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis The Journal of investigative dermatology (2017). PMID: 28433542 DOI: 10.1016/j.jid.2017.03.032 Source material
  3. [3] Naganna N, Opoku-Temeng C, Choi EY, et al. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice EBioMedicine (2019). PMID: 30686755 DOI: 10.1016/j.ebiom.2019.01.012 Source material
  4. [4] Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor Proceedings of the National Academy of Sciences of the United States of America (2014). PMID: 24623852 DOI: 10.1073/pnas.1320661111 Source material

Publications

1 publication citing this product

  1. N Naganna, .et al. , EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755

Added to your cart

View Cart Checkout
Loading...